Treatment options for the management of chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a disease state characterized by the progressive development of airflow limitation that is not fully reversible. The airflow limitation is associated with an abnormal inflammatory response of the lungs to noxious particles or gases. It affects approximately 15 million Americans and is associated with high morbidity and mortality. Previously, pharmacologic therapeutic options were limited by relatively short durations of action in the first-line medications and limited efficacy data and/or a high rate of adverse effects in the second-line medications. Today, there are several new and emerging medications to treat this disease state, and new guidelines have been published for disease management. This review examines current therapeutic options, compares efficacy data, and highlights the recommendations from international guidelines.
A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability
The CEO and founder of a digital behavior company has advice for health plans considering asynchronous behavioral health services like those that his company provides.
In this interview, Melody Chang, RPh, BCOP, MBA, vice president of pharmacy operation at the American Oncology Network, discusses the network's pharmacy strategy and priorities.
The purchase comes as the "big 3" drug wholesalers are coming under scrutiny for their market dominance and the possible perils of vertical integration.
In this discussion, Heather Burrell-Ward, M.D., provides an overview of her recent study that found TMS aimed at the default mode network improved processing speed in schizophrenia.